Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708422 | 0.86 | KDM4E (0.41) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL8582124 | 0.85 | SMN1; SMN2 (0.41) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL25928849 | 0.84 | ACE (0.36) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL8582123 | 0.82 | KDM4E (0.42) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL20100669 | 0.81 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL848463 | 0.79 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL37946 | 0.79 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13322047 | 0.79 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL163861 | 0.79 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| N-Acetylaspartic Acid SCHEMBL31119891 | 0.79 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988340-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-06-05 | — | — | US | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9499526-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | ALAPATI MOHAN MURALI (IN) | 2016-11-17 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-9303038-B2 | Compositions and methods for the treatment of epilepsy and neurological diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9227974-B2 | Compositions and methods for the treatment of respiratory disorders | CELLEX BIO PRIVATE LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-9187427-B2 | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | CELLIX BIO PRIVATE LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | CELLIX BIO PRIVATE LTD (IN) | 2015-05-28 | — | — | US | disclosed |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20150119424-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES | KANDULA MAHESH (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | MAPT 431/4885KDM4E 4703/4885THRB 2512/4885 |
| US-20150291590-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES | KYNU, TKT, SLC5A1 | MAPT 337/4885KDM4E 1692/4885THRB 1592/4885 |
| US-20150119424-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES | SLC6A11, SCN1A, PSEN1 | MAPT 34/4885KDM4E 3923/4885THRB 1000/4885 |
| US-20150148352-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS | KCNH1, TNNT2, TNNC1 | MAPT 782/4885KDM4E 4882/4885THRB 1243/4885 |
| US-20160332950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF UREA CYCLE DISORDERS AND GOUT | SLC14A1, UMPS, UGT1A3 | MAPT 599/4885KDM4E 3071/4885THRB 3033/4885 |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | MAPT 58/4885KDM4E 4683/4885THRB 3647/4885 |
| US-20140107127-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | ACHE, ABCC5, ABCC2 | MAPT 955/4885KDM4E 2596/4885THRB 4771/4885 |
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | PYGB, PSEN1, SI | MAPT 5/4885KDM4E 4494/4885THRB 1446/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | MAPT 431/4885KDM4E 4703/4885THRB 2512/4885 |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | SORD, MUC1, CFTR | MAPT 1246/4885KDM4E 4727/4885THRB 1977/4885 |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | PSEN1, APP, PSEN2 | MAPT 6/4885KDM4E 4823/4885THRB 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.